medigraphic.com
ISSN 0035-0052 (Impreso)

2001, Número 3

<< Anterior

Rev Mex Pediatr 2001; 68 (3)


Cinco razones para no utilizar la vacuna pentavalente en México

Espinosa RF

Idioma: Español
Referencias bibliográficas: 82
Paginas: 112-119
Archivo PDF: 73.44 Kb.


FRAGMENTO

Los chiquillos serán nuestra prioridad, la justificación de todos nuestros empeños

Lic. Vicente Fox Quezada
Presidente de México

México se encuentra en proceso de integración a un mundo globalizado. En esta nueva realidad, las oportunidades y decisiones inteligentes son tomadas en un contexto donde la pluralidad de ideas se valoran debidamente. Hoy se considera anacrónico el tomar decisiones unilaterales que ignoran el cúmulo de información vertida que día a día actualiza el quehacer científico. Como fue expresado por el Presidente Vicente Fox en su discurso de toma de posesión, “En una sociedad plural no cabe la intransigencia, las visiones únicas ni las verdades absolutas”.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Moradpour D, Wands JR. Understanding hepatitis B infection. New Engl J Med 1995; 332: 1092-3.

  2. Anonym. Progress in the control of viral hepatitis: memorandum from a WHO meeting, Bull WHO 1988; 66: 443.

  3. Kane M. Status of hepatitis B immunization programmes in 1998. Vaccine 1998; 16(Suppl):S104-8.

  4. WHO. Hepatitis B (fact sheet WHO/204). In: www.who.int/inf-fs/en/fact204.html.

  5. Bonanni P. Universal hepatitis B immunization: infant and infant plus adolescent immunization. Vaccine 1998; 16: 17-22.

  6. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of hepatitis B by immunization: global perspectives. In: Zuckerman AJ, editor. Viral Hepatitis and Liver Disease. Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease. New York. Alan R Liss 1988: 967-9.

  7. Ghendon Y. Perinatal transmission of hepatitis B virus in high incidence countries. J Virol Methods 1987; 17: 69-79.

  8. Pongpipat D, Suvatte V, Assateerawatts A. Perinatal transmission of hepatitis B virus in Thailand. Asian Pac J Allergy Immunol 1985; 3: 191-3.

  9. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84-92.

  10. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HbeAg and anti-Hbe detection by radio immunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979; 3: 237-41.

  11. Xu Z-Y, Liu C-B, Francis DP et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985; 76: 713-8.

  12. Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York. Grune & Stratton 1984: 209-24.

  13. Stevens CE, Toy PT, Tong MJ et al. Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 1985; 253: 1740-5.

  14. Stevens CE, Taylor PE, Tong MJ et al. Yeast recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257: 2612-6.

  15. ACIP. Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee. MMWR 1991; 40(13): 1-19.

  16. Silveira TR, Fonseca JC, Rivera L et al. Hepatitis B seroprevalence in Latin America. Pan Am J Public Health 1999; 6(6): 378-383.

  17. Alvarez MT, Vázquez JG, Torres FJ et al. Infection of pregnant women with hepatitis B and C viruses and risks for vertical transmission. Archives of Medical Research 1997; 28(3): 415-419.

  18. Datos en archivo. Aventis Pasteur.

  19. Ortiz FJ, Figueroa R, Lara J y cols. Prevalencia de marcadores serológicos de los virus de la hepatitis A, B, C y D en embarazadas. Salud Pública Mex 1996; 38: 317-22.

  20. Decker MD, Edwards KM. Combination Vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, WB Saunders Company 1999: 523.

  21. Greenberg DP, Wong VK, Partridge S et al. Safety and immunogenicity of a combination DTPa-hepatitis B vaccine (DTPa-Hep B) administered to infants at 2, 4 and 6 months of age [abstract 602]. Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America; Arlington, Virginia 1997.

  22. Jilg W, Schmidt M, Dienhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160: 766-9.

  23. Hadler SC, Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine dose on response to vaccine in Yuepa Indians. Vaccine 1989; 7: 106-10.

  24. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001; 19: 877-85.

  25. Kim-Farley RJ, Bart KJ, Schonberger LB et al. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet 1984; 2: 1315-7.

  26. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 1979; 110: 672-92.

  27. Pan American Health Organization. PAHO director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan Am Health Organ 1985; 19: 213-5.

  28. CDC. Update: eradication of paralytic poliomyelitis in the Americas. MMWR 1992; 41: 681-3.

  29. CDC. Certification of poliomyelitis elimination in the Americas. MMWR 1994; 43: 720-2.

  30. Terry LL. The association of cases of poliomyelitis with the use of type III oral poliomyelitis vaccines: a technical report of the United States Surgeon General. Washington, DC. US. Department of Health, Education and Welfare, 1962.

  31. Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral polio vaccines. JAMA 1964; 190: 41-48.

  32. ACIP. Poliomyelitis prevention in the United States. Updated recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 49(RR-05): 1-22.

  33. Andrus JK, Strebel PM, Ciro de Quadros A, Olivé JM. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-1991. Bull WHO 1995; 73(1): 33-40.

  34. Sesión anatomoclínica del jueves 4 de febrero de 1999 del Instituto Nacional de Pediatría. La sesión fue coordinada por el Dr. Mario Acosta Bastidas y los hallazgos anatomoclínicos fueron presentados por el Dr. Antonio Alvarez Mendoza. El niño de un año 4 meses de edad falleció el día 22 de octubre de 1998.

  35. Burgess MA, McIntyre PB. Vaccinc associated paralytie poliomyelitis. CDI 1999; 23: 80-81.

  36. ACIP. Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the advisory committee on immunization practices (ACIP). MMWR 1997; 46(RR-3): 1-25.

  37. Prevots DR, Sutter RW, Strebel PM et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1999. Arch Pediatr Adolesc Med 1994; 148: 479-85.

  38. Van Wezcel A. Growth of cell strains and primary cells on micro carriers in homogenous culture. Nature 1967; 216: 64-65.

  39. Plotkin SA, Murdin A, Vidor E. Inactivated polio vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, WB Saunders Company 1999: 345-363.

  40. McBean A, Thorris M, Albrecht P et al. Serologic response to oral polio vaccines and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128: 615-628.

  41. Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175: S176-S182.

  42. Minor PD. The molecular biology of polio vaccines. J Gen Virol 1992; 73: 3065-3077.

  43. Macadam AJ, Arnold C, Howlett A et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccines. Virology 1989; 172: 408-414.

  44. Martín J, Dunn G, Hull R et al. Evolution of the Sabin strain of Type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 2000; 74(7): 3001-10.

  45. Yoshida H, Horie H, Matsuura K, Miyamura T. Characterization of vaccine-derived polioviruses isolated from sewage and river water in Japan. Lancet 2000; 356: 1461-63.

  46. Outbreak of poliomyelitis-Dominican Republic and Haiti, 2000. MMWR 2000; 49: 1094-1103.

  47. Outbreak of poliomyelitis in Dominican Republic and Haiti: Low vaccination coverage with polio vaccine allows sabin-derived vaccine to circulate. PAHO News Release, Washington, December 1, 2000.

  48. Decker M. Versión por comentario público, Junio de 1998. Presentado en el XIX Congreso de Infectología Pediátrica. Morelia, Michoacán; 2000.

  49. Finn A, Bell F. Polio vaccine: is it time for a change? Arch Dis Child 1998; 78: 571-74.

  50. Anderson P, Peter G, Johnston RB et al. Immunization of humans with polyribophosphate, the capsular antigen of Haemophilus influenzae, type b. J Clin Investig 1972; 51: 39-44.

  51. Peltola H, Käythy H, Virtanen M et al. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 319: 1561-66.

  52. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM 197. Infect Immun 1983; 39: 233-38.

  53. Chu C, Scneerson R, Robbins JB et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococeal type 6ª polysaccharide-protein conjugates. Infect Immun 1983; 40: 245-46.

  54. Gordon LK. Characterization of a hapten-carrier conjugate vaccine: H. Influenzae diphtheria conjugate vaccine. In: Chanock RM, Lerner KA, (eds). Modern approaches to Vaccines. Cold Springs Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1984: 393-96.

  55. Marburg S, Jorn D, Tolman RL et al. Bimolecular chemistry of macromolecules-synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J Am Chem Soc 1986; 108: 5282-97.

  56. Cochi SL, Fleming DW, Hightower AW et al. Primary invasive Haemophilus influenzae type b disease in five western countries. Pediatr Infect Dis J 1985; 12: 362-67.

  57. Peltola H, Virtanen M. Systemic Haemophilus influenzae infections in Finland. Clin Pediatr 1984; 23: 275-80.

  58. Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J Pediatr 1979; 94: 355-64.

  59. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Reviews 2000; 13(2): 302-317.

  60. Macías M, Saltigeral P. Meningitis bacteriana; experiencia en el Instituto Nacional de Pediatría, 1986-1988. Bol Med Hosp Infant Mex 1993; 50(1): 70-71.

  61. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992; 340: 592-94.

  62. ACIP. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b diseases among infants and children two months of age and older. MMWR 1991; 40: 1-7.

  63. Vadheim CM, Greenberg DP, Eriksen E et al. Eradication of Haemophilus influenzae type b disease in Southern California. Arch Pediatr Adolesc Med 1994; 148: 51-56.

  64. Heath PT, Booy R, Azzopardi HJ et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284(18): 2334-40.

  65. Garpenholt O, Hugosson S, Fredlund H et al. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatrica 2000; 89(4): 471-474.

  66. ACIP. Recommendations for use of a Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis and haemophilus b vaccine: Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1993; 42(RR-13): 1-14.

  67. Cherry J. Historical review of pertussis and the classical vaccine. J Infect Dis 1996; 174(Suppl3): S259-S263.

  68. Edwards KM, Decker MD, Mortimer EA. Pertussis vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, WB Saunders Company, 1999; 293-344.

  69. Cherry JD. The epidemiology of pertussis and pertussis vaccine in the United Kingdom and the United States: A comparative study. Curr Probl Pediatr 1984; 14: 1-78.

  70. Kanai K. Japan’s experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Sci Biol 1980; 33: 107-43.

  71. Howson CP, Howe CJ, Fineberg HV, (eds). Adverse effects of pertussis and rubella vaccines. Report of the committee to review the adverse consequences of pertussis and rubella vaccines. Washington, DC, National Academy Press 1991.

  72. Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines: Summary of a report of the Institute of Medicine. JAMA 1992; 267: 392-396.

  73. Howson CP, Fineberg HV. The ricochet of magic bullets: Summary of the Institute of Medicine report: Adverse effects of pertussis and rubella vaccines. Pediatrics 1992; 89: 318-24.

  74. Decker MD et al. Report of the Nationwide multicenter acellular pertussis trial. Sponsored by a grant from the United States Department of Health and Human Services. Pediatrics 1995; 96(suppl).

  75. Ayoyama T. Acellular pertussis vaccines developed in Japan and their application for disease control. J Infect Dis 1996; 174(3): S264-9.

  76. Kimura M et al. Developments in pertussis immunization in Japan. Lancet 1990; 336: 30-32.

  77. Kimura M. Japanese clinical experiences with acellular pertussis vaccines. Dev Biol Stand 1991; 73: 5-9.

  78. ACIP. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use-supplementary ACIP statement: recommendations of the immunization practices advisory committee (ACIP). MMWR 1992; 41(RR-1): 1-10.

  79. ACIP. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series, update to supplementary ACIP statement: recommendations of the immunization practices advisory committee (ACIP). MMWR 1992; 41(RR-15): 1-5.

  80. ACIP. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children: Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1997; 46(RR-7): 1-25.

  81. Álvarez HL, Del Villar P, Schaart W et al. Immunogenicity of the acellular pertussis vaccine combined with diphtheria and tetanus Toxoids (DTaP) and Haemophilus influenzae type b and tetanus toxoid (PRP-T) conjugate vaccine in Mexican children at 18 months of age. Presented at the 8th European Congress of Clinical Microbiology and Infectious Diseases, Abstract Lausanne, Switzerland. 1997; 1408: 25-28.

  82. González SN, Aguilar F, Barreto L et al. Mexican children primed with a pentavalent vaccine (DTaP-IPV and PRP-T). Presented at the ESPID 99. Crete, Greece. Abstract, 1999; 197: 19-21.




2020     |     www.medigraphic.com